DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC,...
One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he...
Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical...
